Long-Term Clinical Outcomes After Bioadaptor vs Onyx Stent Implantation in Patients With Ischemic Heart Disease: 2-Year Follow-Up of the INFINITY-SWEDEHEART Trial
The INFINITY-SWEDEHEART trial demonstrated that among patients with complex ischemic heart disease, treatment with the DynamX Bioadaptor resulted in a significantly lower risk of target lesion failure (TLF: composite of cardiovascular death, target vessel-related MI, or ischemia-driven TLR) between 6 months and 2 years—after the unlocking of the Bioadaptor’s connectors—compared with implantation of the Resolute Onyx (Onyx) stent, according to a study presented by Dr. David Erlinge, Lund University, Sweden, in the Late-Breaking Clinical Science session at TCT 2025.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
